教員業績データベース |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Abatacept ameliorates both glandular and extraglandular involvements in patients with Sjögren's syndrome associated with rheumatoid arthritis: Findings from an open-label, multicentre, 1-year, prospective study: The ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjögren's Syndrome Endocrinopathy) and ROSE II trials. |
掲載誌名 | 正式名:Modern rheumatology ISSNコード:14397609/14397595 |
掲載区分 | 国外 |
巻・号・頁 | 33,pp.160-168 |
著者・共著者 | Tsuboi Hiroto, Toko Hirofumi, Honda Fumika, Abe Saori, Takahashi Hiroyuki, Yagishita Mizuki, Hagiwara Shinya, Ohyama Ayako, Kondo Yuya, Nakano Kazuhisa, Tanaka Yoshiya, Shimizu Toshimasa, Nakamura Hideki, Kawakami Atsushi, Fujieda Yuichiro, Atsumi Tatsuya, Suzuki Yasunori, Kawano Mitsuhiro, Nishina Naoshi, Kaneko Yuko, Takeuchi Tsutomu, Kobayashi Hitomi, Takei Masami, Ogasawara Michihiro, Tamura Naoto, Takasaki Yoshinari, Yokota Kazuhiro, Akiyama Yuji, Mimura Toshihide, Murakami Kosaku, Mimori Tsuneyo, Ohshima Shiro, Azuma Naoto, Sano Hajime, Nishiyama Susumu, Matsumoto Isao, Sumida Takayuki. |
発行年月 | 2023/01 |
概要 | OBJECTIVE: To clarify the efficacy and safety of intravenous abatacept for glandular and extraglandular involvements in Sjögren's syndrome (SS) associated with rheumatoid arthritis (RA). MATERIALS AND METHODS: We performed an open-label, prospective, 1-year, observational multicenter study (ROSE and ROSE II trials). The primary endpoint was the remission rate as measured by SDAI at 52 weeks. The secondary endpoints included the chpatients (36 in ROSE and 32 in ROSE II, all women) were enrolled. SDAI decreased significantly from 23.6 ± 13.2 at baseline to 9.9 ± 9.5 at 52 weeks. Patients with SDAI remission increased from 0 (0 weeks) to 19 patients (27.9%) at 52 weeks. Saliva volume increased significantly at 24 weeks. Tear volume increased significantly at 52 weeks. Both ESSDAI and ESSPRI were significantly decreased at 12 weeks, |